Safety of anticoagulants and antiplatelet drugs in patients with recurrent spontaneous abortion during pregnancy
10.3969/j.issn.1674-8115.2020.03.021
- Author:
Si SUN
1
Author Information
1. Department of Obstetrics and Gynecology, Renji Hospital, Shanghai Jiao Tong University School of Medicine
- Publication Type:Journal Article
- Keywords:
Anticoagulants;
Antiplatelet drug;
Aspirin;
Heparin;
Heparinoid;
Recurrent spontaneous abortion;
Safety;
Warfarin
- From:
Journal of Shanghai Jiaotong University(Medical Science)
2020;40(3):402-407
- CountryChina
- Language:Chinese
-
Abstract:
Recurrent spontaneous abortion (RSA) is defined as the loss of at least two consecutive pregnancies before the 28th week of gestation. RSA is a complicated pathological condition caused by multiple factors including genetic abnormalities, anatomical factors, endocrine disorders, immune abnormalities, prethrombotic state (PTS) and infection factors. Studies have suggested that anticoagulation and antiplatelet therapy could significantly improve the pregnancy outcomes of RSA patients with PTS and autoimmune abnormalities. Frequently used anticoagulants and antiplatelet drugs are heparin, heparinoid, warfarin, aspirin and clopidogrel. However, the maternal and fetal safety after the use of these drugs during pregnancy has long been concerned. Safety of anticoagulants and antiplatelet drugs in patients with recurrent spontaneous abortion during pregnancy is reviewed.
